Mass-producible immune cells kill patient-derived colorectal tumors in mice

edited by Sadie Harley , reviewed by Robert Egan

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

Add as preferred source Kobe University stem cell researcher AOI Takashi and his team report that they created iPS cells from a subclass of T cells that can be used across patients and could reproducibly turn them back into T cells with an overall 80,000-fold multiplication and without using animal cells or extracts, and that the resulting T cells attack and shrink human patient-derived colorectal cancer tumors that were implanted into mice. Credit: AOI Takashi Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted in mice. The Kobe University development is a significant contribution toward faster, cheaper cancer immunotherapy.